Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease
Our study found that genetically proxied GLP-1 receptor agonism is associated with lower burden of clinical and imaging cSVD outcomes. These findings provide a rationale for clinical trials evaluating GLP-1 receptor agonists as a potential strategy to prevent cSVD progression.
Authors
- Marios K. Georgakis (ORCID: https://orcid.org/0000-0003-3507-3659)
- Murad Omarov (ORCID: https://orcid.org/0000-0001-6126-8631)
- Panagiotis Zangas (ORCID: https://orcid.org/0009-0006-1350-4154)
Institutions
- Broad Institute (US)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Neurology Genetics
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1212/nxg.0000000000200359
- Primary Topic
- Cerebrovascular and genetic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft